MoonLake Immunotherapeutics disclosed Phase 2 data showing a clinically meaningful benefit in an aggressive inflammatory arthritis cohort and said the result increases its confidence ahead of an FDA submission. The company shared topline outcomes with Endpoints News and framed the readout as supportive of its regulatory path. Details on endpoints and effect sizes were limited in the company's public disclosure; MoonLake indicated the dataset will inform its dossier and next‑step discussions with regulators as it prepares for a potential filing.